

## PROGRAM

### June 10 (1<sup>st</sup> day)

08:30 OPENING REMARKS

#### ●Basic Science I. EGFR

Chairpersons: C. David James (USA), Motoo Nagane (Japan)

- 08:45 **BS 1** THE ROLE OF EGF RECEPTOR HETEROGENEITY IN DRIVING GLIOMA DEVELOPMENT  
*Frank Furnari (USA)*
- 09:00 **BS 2** ABERRANT EGFR SIGNALING IN GLIOMA  
*Oliver Boegler (USA)*
- 09:15 **BS 3** THE ROLE OF EGFR\* SIGNALING PATHWAY FOR TUMOR MAINTENANCE AND ALTERNATIVE PATHWAYS IN GLIOBLASTOMA WHICH ENHANCE TUMOR GROWTH  
*Akitake Mukasa (Japan)*
- 09:30 **BS 4** EGF RECEPTOR TYROSINE KINASE MEDIATES A NOVEL PATHWAY OF DRUG RESISTANCE IN MALIGNANT GLIOMAS VIA TYROSINE PHOSPHORYLATION AND FUNCTIONAL ACTIVATION OF GLUTATHIONE S- TRANSFERASE P1  
*Tatsunori Okamura (USA)*

#### ●Basic Science II. Genetic and Expression Profile. Markers.

Chairpersons: Rolf Bjerkvig (Norway), Chifumi Kitanaka (Japan)

- 09:55 **BS 5** MULTIGENE PREDICTOR OF OUTCOME IN NEWLY DIAGNOSED GLIOBLASTOMA  
*Kenneth D. Aldape (USA)*
- 10:10 **BS 6** USING GENE EXPRESSION PROFILING TO IDENTIFY A PROGNOSTIC MOLECULAR SPECTRUM IN GLIOMAS  
*Mitsuaki Shirahata (Japan)*
- 10:20 **BS 7** SPHINGOSINE-1-PHOSPHATE1 RECEPTOR REGULATES GLIOMA CELL PROLIFERATION AND CORRELATES WITH SURVIVAL OF PATIENTS WITH GLIOBLASTOMA  
*Yuya Yoshida (Japan)*

10:30 Coffee Break

#### ●Basic Science III. Invasion, Immuno-resistance

Chairpersons: Frank Furnari (USA), Mitsutoshi Nakada (Japan)

- 11:00 **BS 8** \*17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN DOWN- REGULATES HYALURONIC ACID-INDUCED GLIOMA INVASION BY BLOCKING MMP-9 SECRETION  
*Seung H Lee (Korea)*
- 11:03 **BS 9** \*INHIBITION OF GLIOMA INVASION BY SILENCING SPARC WITH SIRNA  
*Takanori Ohnishi (Japan)*
- 11:06 **BS 10** \*THE ROLE OF CHEMOKINE, SDF-1 AND CXCR4 IN GLIOMA ANGIOGENESIS AND INVASIVENESS: INTERACTION BETWEEN GLIOMA AND GLIOMA DERIVED ENDOTHELIAL CELLS  
*Shingo Takano (Japan)*
- 11:10 **BS 11** THE GUANINE NUCLEOTIDE EXCHANGE FACTORS TRIO, ECT2, AND VAV3 MEDIATE THE INVASIVE BEHAVIOR OF GLIOBLASTOMA  
*James Rutka (Canada)*
- 11:20 **BS 12** ELMO1 AND DOCK180, A BIPARTITE RAC1 GUANINE NUCLEOTIDE EXCHANGE FACTOR, PROMOTE HUMAN GLIOMA CELL INVASION  
*Shiyuan Cheng (USA)*
- 11:30 **BS 13** A NOVEL SWITCH THAT LINKS PTEN TO THE CONTROL OF UBIQUITINATION, TRAIL SENSITIVITY, AND IMMUNORESISTANCE IN HUMAN GBM XENOGRAFT CELLS  
*Russell O. Pieper (USA)*

\*Posters are also displayed in the Poster Viewing Room.

## ●Lunchtime Seminar: Temozolomide plus Interferon-beta for newly diagnosed GBM: INTEGRA study

(Sponsor: Toray Industries Co., Ltd.)

**Chairperson:** Soichiro Shibui (Japan)

- 12:00 **LS** A JAPANESE MULTICENTER CLINICAL TRIAL OF INTERFERON-B AND TEMOZOLOMIDE COMBINATION THERAPY FOR HIGH-GRADE GLIOMAS: FROM BENCH TO BEDSIDE  
*Atsushi Natsume (Japan), Toshihiko Wakabayashi (Japan)*

## ●New Therapeutic Approaches I

**Chairpersons:** Mitchel S. Berger (USA), Keisuke Ueki (Japan)

- 13:00 **New 1** ENHANCING GLIOBLASTOMA CYTOTOXIC THERAPY THROUGH SMALL MOLECULE INHIBITION OF P53  
*C. David James (USA)*
- 13:10 **New 2** CYCLIN-DEPENDENT KINASE INHIBITOR FLAVOPIRIDOL ENHANCES CYTOTOXIC ACTION OF DNA-DAMAGING AGENTS ON HUMAN GLIOMA CELLS  
*Yuichi Hirose (Japan)*
- 13:20 **New 4** BORON NEUTRON CAPTURE THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA  
*Shin-Ichi Miyatake (Japan)*
- 13:30 **New 5** MODULAR RECOMBINANT TRANSPORTERS: A FLEXIBLE PLATFORM FOR BRAIN TUMOR TARGETED RADIONUCLIDE THERAPY  
*Michael R. Zalutsky (USA)*
- 13:40 **New 6** NANO-PARTICLE MICELLE AS A DRUG DELIVERY SYSTEM FOR BRAIN TUMOR THERAPY  
*Yasushi Ino (Japan)*
- 13:50 **New 7** MR PARAMETERS AS NON-INVASIVE BIOMARKERS FOR PREDICTING SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA MULTIFORME  
*Susan M. Chang (USA)*
- 14:05 **New 8** TREATMENT OF CNS RADIATION NECROSIS WITH BEVACIZUMAB, AN ANTI-VEGF ANTIBODY  
*Victor A. Levin (USA)*
- 14:20 **Stem 8** TUMOR-DERIVED MESENCHYMAL STEM CELLS IN HUMAN GLIOMAS  
*Frederick F. Lang (USA)*
- 14:30 Coffee Break

## ●Evening Symposium: Clinical Trials and Related Information

(Sponsor: Schering-Plough K.K.)

**Chairpersons:** Jan Buckner (USA), Tomokazu Aoki (Japan)

- 15:00 **CT 10** A CLINICAL TRIAL FOR MALIGNANT GLOMAS BY JCOG-BRAIN TUMOR STUDY GROUP (JCOG 0305)  
*Soichiro Shibui (Japan)*
- 15:12 **CT 11** PROGNOSTIC VARIABLES IN RECURRENT HIGH-GRADE GLIOMA CLINICAL TRIALS: AN NCCTG AND NABTC JOINT ANALYSIS  
*Jan Buckner (USA)*
- 15:32 **CT 12** A PHASE I/IB STUDY OF TEMOZOLOMIDE (TMZ) AND THE FARNESYLTRANSFERASE INHIBITOR, LONAFARNIB (SARAZARTM, SCH66336) IN RECURRENT, TMZ REFRACTORY GLIOBLASTOMA (GBM)  
*Mark R. Gilbert (USA)*
- 15:44 **CT 13** Metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma  
*Jong-Hyun Kim (Korea)*

- 15:56 **CT 14** AN INTERGROUP PHASE III STUDY OF RADIATION THERAPY WITH OR WITHOUT TEMOZOLOMIDE FOR SYMPTOMATIC OR PROGRESSIVE LOW-GRADE GLIOMAS  
*David Schiff (USA)*
- 16:08 **CT 15** THE EORTC BRAIN TUMOR GROUP: CURRENT DEVELOPMENTS  
*Martin J. van den Bent (Netherlands)*
- 17:30-19:30 Garden Party

## ●Poster Presentation

Chairperson: Kazuhiko Mishima (Japan)

- 20:30 **CT 1** TREATMENT RESULT OF ANAPLASTIC OLIGODENDROGLIOMAS: PERSONAL EXPERIENCE  
*Young-Cho Koh (Korea)*
- 20:33 **CT 2** BRAIN ATROPHY AND COGNITIVE FUNCTION FOLLOWING CHEMOTHERAPY TO OLIGODENDROGLIOMA  
*Keisuke Ueki (Japan)*
- 20:36 **CT 3** AN ULTRASTRUCTURAL, IMMUNOHISTOCHEMICAL AND MORPHOMETRIC STUDY OF OLIGODENDROGLIOMAS WITH RESPECT TO CHROMOSOME 1P DELETION  
*Takashi Komori (Japan)*
- 20:39 **CT 4** GENETIC PROFILE IN 1P- AND 19Q- DELETED OLIGODENDROGLIOMA WITH SHORT RELAPSE-FREE SURVIVAL  
*Jun-ichi Adachi (Japan)*
- 20:42 **CT 5** DIFFERENTIAL ASSOCIATION OF CHROMOSOME 19 SNP VARIANTS WITH OLIGODENDROGLIOMA: A CASE-CASE COMPARISON  
*Robert B. Jenkins (USA)*
- 20:45 **CT 6** AGE, PREOPERATIVE KPS AND MGMT PROMOTOR HYPERMETHYLATION DEFINE THE SURVIVAL OF THE PATIENTS WITH GLIOBLASTOMA  
*Yukihiko Sonoda (Japan)*
- 20:48 **CT 7** MGMT PROMOTER METHYLATION STATUS IS A STRONG PREDICTIVE FACTOR FOR RESPONSE TO ACNU (NITROSOUREA) BASED RADIATION THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMAS  
*Yoshitaka Narita (Japan)*
- 20:51 **CT 9** PHASE II STUDY OF LOW DOSE ICE (IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE) FOR RECURRENT GLIOBLASTOMA  
*Tomokazu Aoki (Japan)*
- 20:54 **BS 14** CENTROSOME AMPLIFICATION INDUCED BY SURVIVIN SUPPRESSION ENHANCES BOTH CHROMOSOME INSTABILITY AND RADIOSENSITIVITY IN GLIOMA CELLS  
*Kaoru Kurisu (Japan)*
- 20:57 **BS 15** THE WARBURG EFFECT AND TUMOR CELL SURVIVAL IN HUMAN GBM  
*Abhijit Guha (Canada)*
- 21:00 **BS 16** GENETIC AND HYPOXIC MECHANISMS OF TISSUE FACTOR EXPRESSION AND THROMBOSIS IN GLIOBLASTOMA  
*Daniel J. Brat (USA)*
- 21:03 **BS 17** GATA4 EXPRESSION IN THE NORMAL CNS AND ITS FREQUENT LOSS IN HUMAN GLIOMAS  
*Abhijit Guha (Canada)*
- 21:06 **BS 18** THE EXPRESSION LEVEL OF S1P1 IS RELATED TO MIB-1 LABELING INDEX WHICH PREDICTS SURVIVAL IN GLIOBLASTOMA  
*Mitsutoshi Nakada (Japan)*
- 21:09 **BS 19** ENHANCED TUMOR GROWTH ELICITED BY L- TYPE AMINO ACID TRANSPORTER 1 IN HUMAN MALIGNANT GLIOMA CELLS  
*Motoo Nagane (Japan)*
- 21:12 **BS 20** THE RNA BINDING PROTEIN 76 CONTROLS GENE EXPRESSION IN GBM  
*Matthias Gromeier (USA)*

\*Posters are also displayed in the Poster Viewing Room.

- 21:15 **BS 21** EXPRESSION AND FUNCTIONAL SIGNIFICANCE OF INHIBITORS OF APOPTOSIS PROTEINS (IAPs) IN HUMAN GLIOMAS  
*Abhijit Guha (Canada)*
- 21:18 **BS 22** DUAL BLOCKADE OF LIPID AND PROTEIN KINASES DRIVES APOPTOSIS IN GLIOMA  
*William A. Weiss (USA)*
- 21:21 **BS 23** TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS.  
*Jian Wang (Norway)*
- 21:24 **BS 24** THE ROLE OF GLIAL CELLS IN BRAIN METASTASES OF TUMOR CELLS  
*Mami Noda (Japan)*
- 21:27 **BS 27** FORMATION AND FUNCTIONAL MAPPING OF THE INTERACTION DOMAIN OF A PHYSICAL COMPLEX BETWEEN TGM2 AND GSTP1 THAT CONFERS CISPLATIN RESISTANCE IN MALIGNANT GLIOMA CELLS  
*Francis Ali-Osman (USA)*

## June 11 (2<sup>nd</sup> day)

### ● Cancer Stem Cell

Chairpersons: Manfred Westphal (Germany), Hideyuki Saya (Japan)

- Cancelled** **Stem 1** THE REAL AXIS OF EVIL: CANCER STEM CELLS IN TUMOR GROWTH, THERAPEUTIC RESISTANCE, AND ANGIOGENESIS  
*Anita B. Hjelmeland (USA)*
- 08:30 **Stem 2** A HIERARCHY OF SELF-RENEWING TUMOR-INITIATING CELL TYPES IN GLIOBLASTOMA  
*Heidi S. Phillips (USA)*
- 08:45 **Stem 3** CHARACTERIZATION AND TRANSFORMATION POTENTIAL OF SYNTHETIC ASTROCYTES DIFFERENTIATED FROM MURINE EMBRYONIC STEM CELLS  
*Abhijit Guha (Canada)*
- 09:00 **Stem 4** CLINICAL AND BIOLOGICAL IMPLICATION OF CD133 POSITIVE AND NEGATIVE CELLS IN GLIOBLASTOMAS  
*Do-Hyun Nam (Korea)*
- 09:15 **Stem 5** CD133 POSITIVE CELLS ARE STABLY ENTRAPPED IN SHORT-TERM CELL LINES DERIVED FROM MALIGNANT ASTROCYTOMA AND CONTRIBUTE TO CHEMORESISTANCE  
*John L. Darling (UK)*
- 09:30 **Discussion**
- 09:45 Coffee Break
- 10:15 **Stem 6** CANDIDATE STEM CELL POPULATION FOR USE IN CNS TUMOR THERAPY  
*Catherine T. Flores (UK)*
- 10:30 **Stem 7** HUMAN ADULT BRAIN CONTAINS NEURO-GLIAL PROGENITOR CELLS WHICH TARGET HUMAN GLIOMA XENOGRAFTS  
*Manfred Westphal (Germany)*
- 10:45 **Stem 9** CEREBELLAR STEM CELLS LACKING RB AND P53 ACT AS TUMOUR INITIATING CELLS IN MEDULLOBLASTOMA PATHOGENESIS  
*Silvia Marino (UK)*
- 11:00 **Stem 10** GLOBAL ANALYSES OF POLYCOMB MEDIATED TRANSCRIPTIONAL REPRESSION AND DNA METHYLATION TARGETS IN BRAIN TUMOR STEM CELLS  
*Atsushi Natsume (Japan)*
- 11:15 **Discussion**

12:00

### ●Lunchtime Symposium: Primary CNS Lymphoma

(Sponsor: Chugai Pharmaceutical Co., Ltd.)

**Chairpersons:** Brian Patrick O'Neill (USA), Takanori Ohnishi (Japan)

- 12:15 **PCNSL 1** PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN JAPAN: CHANGES IN CLINICAL FEATURES, TREATMENT AND PROGNOSIS DURING 1985-2004  
*Yuta Shibamoto (Japan)*
- 12:30 **PCNSL 2** RESPONSE AND SURVIVAL PATTERN IN PRIMARY CNS LYMPHOMA TREATED BY HIGH DOSE METHOTREXATE MONOCHEMOTHERAPY: ROLE OF STAT6 AS PROGNOSTIC DETERMINANT  
*Yong-Kil Hong (Korea)*
- 12:45 **PCNSL 3** IMMUNOCHEMOTHERAPY WITH RITUXIMAB IN CONJUNCTION WITH BLOOD-BRAIN BARRIER DISRUPTION AND AN ICE REGIMEN FOR RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS (PCNSL)  
*Kazuhiko Mishima (Japan)*
- 13:00 **PCNSL 4** \*RACIAL/ETHNIC DIFFERENCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A SEER-BASED ESTIMATE OF INCIDENCE AND SURVIVAL RATES AMONG UNITED STATES BLACKS, WHITES, ASIAN/PACIFIC ISLANDERS AND AMERICAN INDIANS/ALASKAN NATIVES  
*Brian Patrick O'Neill (USA)*
- 13:03 **PCNSL 5** \*DEL (6)(Q22) AND BCL6 REARRANGEMENTS DETECTED BY INTERPHASE FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) ARE UNFAVORABLE CYTOGENETIC ABNORMALITIES IN IMMUNOCOMPETENT (IC) PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)  
*Brian Patrick O'Neill (USA)*

### ●Molecular Targeted Therapies

(Sponsor: Daiichi Sankyo Co., Ltd.)

**Chairpersons:** Martin J. van den Bent (Netherlands), John L. Darling (UK)

- 13:45 **IL** BIOMARKERS FOR PREDICTIVE AND PROGNOSTIC FACTORS  
(Invited Lecture) *Kazuto Nishio (Japan)*
- 14:25 **MTT 1** PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME  
*David A. Reardon (USA)*
- 14:45 **MTT 3** FEASIBILITY/TOLERABILITY RESULTS FROM A PHASE I/II STUDY OF TEMSIROLIMUS (CCI-779) AND SORAFENIB IN RECURRENT GLIOBLASTOMA: NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) N0572  
*David Schiff (USA)*
- 14:57 **MTT 4** PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TEMSIROLIMUS) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)  
*Patrick Wen (USA)*
- 15:30 Hakodate Sightseeing & Dinner

## June 12 (3<sup>rd</sup> day)

### ●New Therapeutic Approaches II

**Chairpersons:** James Rutka (Canada), Tomoki Todo (Japan)

- 08:30 **New 17** \*A CLINICAL TRIAL OF CATIONIC LIPOSOMES CONTAINING INTERFERON-BETA GENE FOR PATIENTS WITH MALIGNANT GLIOMA  
*Toshihiko Wakabayashi (Japan)*
- 08:33 **New 18** \*ANTI-EGF-R ANTIBODIES IN A HIGHLY INVASIVE XENOTRANSPLANT MODEL OF HUMAN GLIOMA  
*Manfred Westphal (Germany)*

\*Posters are also displayed in the Poster Viewing Room.

- 08:36 **New 19** \*DICER-REGULATED MICRO RNAS 222 AND 339 PROMOTE IMMUNE-ESCAPE OF CANCER CELLS THROUGH DOWNREGULATION OF ICAM-1  
*Hideho Okada (USA)*
- 08:39 **New 20** \*THE DNA DEMETHYLATING AGENT 5- AZA-2-DEOXYCYTIDINE INDUCES THE EXPRESSION OF CANCER-TESTIS ANTIGENS IN HUMAN GLIOMAS: EPIGENETIC TARGET FOR TUMOR IMMUNOTHERAPY  
*Atsushi Natsume (Japan)*
- 08:42 **New 22** \*WT1 (WILMS TUMOR GENE) PEPTIDE VACCINATION FOR PATIENTS WITH RECURRENT GLIOBLASTOMA  
*Shuichi Izumoto (Japan)*
- 08:45 **New 23** \*IDENTIFICATION OF AN HLA- A24-RESTRICTED T-CELL EPI TOPE DERIVED FROM A GLIOMA-ASSOCIATED ANTIGEN, INTERLEUKIN 13 RECEPTOR ALPHA 2 CHAIN  
*Toshihiko Wakabayashi (Japan)*
- 08:48 **New 9** EXPERIMENTAL BRAIN TUMOR THERAPY USING ONCOLYTIC HSV-1 ARMED WITH INTERLEUKIN 12  
*Tomoki Todo (Japan)*
- 08:58 **New 11** DUAL-SPECIFIC IMMUNOTOXIN, D2C7 (scdsFv)-PE38KDEL, FOR BRAIN TUMOR TREATMENT  
*Chien-Tsun Kuan (USA)*
- 09:08 **New 12** RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY  
*Kenji Wakiya (Japan)*
- 09:18 **New 13** INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII POSITIVE GBM  
*Gary E. Archer (USA)*
- 09:28 **New 14** TYPE-1 DENDRITIC CELL (DC) VACCINES IN COMBINATION WITH POLY-ICLC IN PARTICIPANTS WITH RECURRENT MALIGNANT GLIOMA  
*Hideho Okada (USA)*
- 09:38 **New 15** EFFICACY OF A RNA-PULSED DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS ANTIGENS IN NEWLY- DIAGNOSED GBM  
*Duane A. Mitchel (USA)*
- 09:48 **New 16** REAL TIME MONITORING FOR CONVECTION-ENHANCED DELIVERY OF INTRATUMORAL CHEMOTHERAPY IS PREDICTIVE OF RESPONSE IN CANINE SPONTANEOUS GLIOMAS  
*Krystof S. Bankiewicz (USA)*
- 10:00 **Discussion**
- 10:20 Coffee Break

## ●Pediatric Neuro-Oncology: CNSGCT

**Chairpersons:** Jonathan Finlay (USA), Masao Matsutani (Japan)

- 11:00 **PNO 1** TREATMENT OF PRIMARY CNS GERMINOMATOUS GERM CELL TUMORS (GCT) WITH CHEMOTHERAPY PRIOR TO REDUCED DOSE VENTRICULAR FIELD IRRADIATION: THE CHILDRENS HOSPITAL LOS ANGELES EXPERIENCE 2003-2007  
*Jonathan Finlay (USA)*
- 11:20 **PNO 2** LOW-DOSE RADIOTHERAPY AFTER INDUCTION CHEMOTHERAPY FOR INTRACRANIAL GERMINOMAS  
*Yutaka Sawamura (Japan)*
- 11:40 **PNO 3** TREATMENT RESULTS OF CONSECUTIVE 78 PATIENTS WITH INTRACRANIAL GERMINOMA IN A SINGLE INSTITUTE  
*Toshihiro Kumabe (Japan)*
- 11:50 **PNO 4** \*CLINICAL EVALUATION OF PINEAL PARENCHYMAL TUMORS -HIROSHIMA UNIVERSITY HOSPITAL EXPERIENCES-  
*Kazuhiko Sugiyama (Japan)*
- 11:53 **PNO 6** \*ENHANCED EXPRESSION OF DNA TOPOISOMERASE II GENES IN HUMAN MEDULLOBLASTOMA AND ITS POSSIBLE ASSOCIATION WITH ETOPOSIDE SENSITIVITY  
*Tadahisa Shono (Japan)*

\*Posters are also displayed in the Poster Viewing Room.



- 11:56 **PNO 7** \*IDENTIFICATION OF GENES AND PATHWAYS CRITICAL FOR TUMOR INITIATION, MAINTENANCE, AND PROGRESSION IN A MURINE MODEL OF LEPTOMENINGEAL METASTATIC MEDULLOBLASTOMA DRIVEN BY THE SLEEPING BEAUTY TRANSPOSON  
*Michael D. Taylor (Canada)*
- 11:59 **PNO 8** \*IDENTIFICATION OF NT-3/TRK-C REGULATED PROTEINS IN MEDULLOBLASTOMA  
*Irene Slavic (Austria)*
- 12:02 **PNO 10** \*FACTORS AFFECTING OF MEDULLOBLASTOMAS IN CHILDREN  
*Tai-T Wong (Taiwan)*
- 12:10 LUNCH

### ●Medulloblastoma, PNET, AT/RT, Choroid plexus tumor

**Chairpersons:** Mark W. Kieran (USA), Takaaki Yanagisawa (Japan)

- 13:30 **PNO 11** ADULTS WITH MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT  
*Jonathan Finlay (USA)*
- 13:50 **PNO 12** TREATMENT OF ORTHOTOPIC MEDULLOBLASTOMAS WITH METRONOMIC TEMOZOLOMIDE AND 13-CIS-RETINOIC ACID  
*Anat Erdreich-Epstein (USA)*
- 14:00 **PNO 13** MEDULLOBLASTOMA GROWTH ENHANCEMENT BY HGF/SF EXPRESSION IN CEREBELLAR NEURAL PROGENITOR CELLS IS SUPPRESSED BY SYSTEMIC ANTIBODY TREATMENT  
*Daniel W. Fults (USA)*
- 14:12 **PNO 14** OTX2 is oncogenic and predicts decreased survival in medulloblastomas patients  
*Sridharan Gururangan (USA)*
- 14:24 **PNO 16** RESULTS FROM A SINGLE-ARM, MULTI- INSTITUTIONAL PHASE II STUDY OF MULTI-AGENT INTRATHECAL AND SYSTEMIC CHEMOTHERAPY WITH AGE- AND RISK-ADAPTED RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED CNS ATYPICAL TERATOID/RHABDOID TUMOR  
*Mark W. Kieran (USA)*
- 14:36 **PNO 17** CPT-SIOP-2000 STUDY: A PLANET WIDE CHOROID PLEXUS TUMOR STUDY - INTERIM REPORT OCTOBER 2007  
*Johannes E. A. Wolff (USA)*
- 15:00 Coffee Break

### ●Neurocognitive function and outcome

**Chairperson:** Ryo Nishikawa (Japan)

- 15:30 **OUT 1** LATE EFFECTS FOLLOW-UP OF HEAD START II SURVIVORS  
*Stephen Sands (USA)*
- 15:40 **OUT 2** NEUROPSYCHOLOGICAL OUTCOME OF SURVIVORS OF PEDIATRIC MALIGNANT GLIOMA  
*Stephen Sands (USA)*
- 16:00 **CLOSING REMARKS**
- 18:30-21:00  
**FAREWELL DINNER**